Loading...
XASX
CGS
Market cap288mUSD
Dec 05, Last price  
2.54AUD
1D
0.79%
1Q
47.67%
Jan 2017
109.25%
IPO
421.85%
Name

CogState Ltd

Chart & Performance

D1W1MN
XASX:CGS chart
P/E
28.48
P/S
5.69
EPS
0.06
Div Yield, %
Shrs. gr., 5y
1.77%
Rev. gr., 5y
8.39%
Revenues
51m
-23.33%
1,540,4481,993,0923,619,8346,770,9398,060,9848,692,53512,295,48511,373,51411,547,84812,328,28327,252,05535,012,76537,371,44430,531,04933,967,94843,818,79862,025,51660,137,14766,272,81350,812,535
Net income
10m
+86.15%
0001,153,7861,391,76002,509,3250002,641,919-853,062-730,367-3,489,836-2,918,6497,015,64510,369,3125,304,0135,449,88410,144,735
CFO
11m
+32.32%
-1,584,536-1,353,744-704,537914,5751,408,847510,1881,290,976-1,627,592-3,409,015-2,776,9252,630,5783,242,491-101,937608,3621,111,59021,605,92813,454,9941,760,4368,672,57611,475,200

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Cogstate Limited, a neuroscience technology company, provides computerized cognitive tests and electronic clinical outcome assessment solutions. The company's cognitive services include project management, data management, scientific consulting, statistical analysis, scales procurement, rater training, and monitoring solutions. It operates in Clinical Trials and Healthcare segments. The Clinical Trials segment provides technology and associated services that are used to quantify the effect of diseases and drugs, and devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The Healthcare segment provides Cognigram, a system for regular and standardized testing to assist primary care physicians and/or hospitals in the early detection of cognitive decline. As of June 30, 2022, it had participated in approximately 1,800 academic research. Cogstate Limited was incorporated in 1999 and is based in Melbourne, Australia.
IPO date
Feb 13, 2004
Employees
172
Domiciled in
AU
Incorporated in
AU

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT